Serenex (Durham) an integrated oncology-focused drug discovery and development company announced the initiation of a phase 1 trial for SNX-5422, its novel heat shock protein 90 (Hsp90) inhibitor. SNX-5422 is a small molecule delivered orally and was discovered internally using Serenex's proprietary chemoproteomics technology platform.
"Based on recent research and discoveries, the scientific and medical communities have recognized Hsp90 inhibitors as a promising tool in the fight against cancer both as single agents and in combination with other therapies," said Dr. Richard Kent, company president and chief executive officer. "With the start of this trial, SNX-5422 becomes one of the very few totally synthetic, orally bioavailable Hsp90 inhibitors in the clinic."
The first phase 1 study will be a dose escalating trial involving up to 50 patients. The trial will evaluate safety, pharmacokinetic and pharmacodynamic properties of SNX-5422. This clinical trial will be conducted at the TGen Clinical Research Services at Scottsdale Healthcare in Scottsdale, AZ and at the Sarah Cannon Research Institute in Nashville, TN.
"We're excited to be studying SNX-5422 in clinical trials and assessing the potential of this oral Hsp90 inhibitor as a novel therapeutic option for cancer patients," said Dr. Howard Burris, director of drug development, at the Sarah Cannon Research Institute.
